Induction of experimental myasthenia gravis in Rhesus monkeys: a model for the study of the human disease
P. R. health sci. j
; 5(1): 13-8, Apr. 1986. tab
Article
in En
| LILACS
| ID: lil-96437
Responsible library:
BR1.1
RESUMO
Experimental autoimmune myasthenia gravis (EAMG) was induced in thesus monkeys using purified acetylcholine recptor (AChR) from Torpedo california. A single dose of 80 µg induced antibody formation two weeks after injection. Two subsequent doses at two-week intervals caused clinical signs (anorexia, fatigability, weight loss, ptosis and dysphagia) which initially responded to treatment with neostigmine. Histologic examination of post-mortem tissues revealed lesions characteristic of myasthenia gravis in man musuclar atrophy, fibrous degeneration and lymphocytic infiltration. Antibodies were quantitated in the sera of three other monkeys which received only 60 µg of purified AChR. Abnormally high titers persisted for two years (60-200µg/ml versus 0-10µg/ml for controls). A monkey injected with 60µgAChR as part of reconstituted membrane vesicles had lower titers (30-50µg/ml) than those which received purified receptor. Only those monkeys with antibody titers exceeding 800 µg/ml developed overt disease. These titers were 4-100 times higher than those reported for myasthenic humans. The antibody-antigen molar ratios were higher for monkeys with disease than for asymptomatic animals. These data suggest that the diversity of antibody molecules synthesized by the sensitized monkeys determined the appearance of clinical signs, and that the cross reaction of tanti-torpedo antivodies with monkey receptor was primarily responsible for the development of EAMG
Search on Google
Collection:
01-internacional
Database:
LILACS
Main subject:
Myasthenia Gravis
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
P. R. health sci. j
Journal subject:
MEDICINA
Year:
1986
Document type:
Article